Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies

Open access

Abstract

OBJECTIVE: To synthesise evidence on the average bias and heterogeneity associated with reported methodological features of randomized trials. DESIGN: Systematic review of meta-epidemiological studies. METHODS: We retrieved eligible studies included in a recent AHRQ-EPC review on this topic (latest search September 2012), and searched Ovid MEDLINE and Ovid EMBASE for studies indexed from Jan 2012-May 2015. Data were extracted by one author and verified by another. We combined estimates of average bias (e.g. ratio of odds ratios (ROR) or difference in standardised mean differences (dSMD)) in meta-analyses using the random-effects model. Analyses were stratified by type of outcome ("mortality" versus "other objective" versus "subjective"). Direction of effect was standardised so that ROR < 1 and dSMD < 0 denotes a larger intervention effect estimate in trials with an inadequate or unclear (versus adequate) characteristic. RESULTS: We included 24 studies. The available evidence suggests that intervention effect estimates may be exaggerated in trials with inadequate/unclear (versus adequate) sequence generation (ROR 0.93, 95% CI 0.86 to 0.99; 7 studies) and allocation concealment (ROR 0.90, 95% CI 0.84 to 0.97; 7 studies). For these characteristics, the average bias appeared to be larger in trials of subjective outcomes compared with other objective outcomes. Also, intervention effects for subjective outcomes appear to be exaggerated in trials with lack of/unclear blinding of participants (versus blinding) (dSMD -0.37, 95% CI -0.77 to 0.04; 2 studies), lack of/unclear blinding of outcome assessors (ROR 0.64, 95% CI 0.43 to 0.96; 1 study) and lack of/unclear double blinding (ROR 0.77, 95% CI 0.61 to 0.93; 1 study). The influence of other characteristics (e.g. unblinded trial personnel, attrition) is unclear. CONCLUSIONS: Certain characteristics of randomized trials may exaggerate intervention effect estimates. The average bias appears to be greatest in trials of subjective outcomes. More research on several characteristics, particularly attrition and selective reporting, is needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0159267

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Conceptual framework that underlies the Cochrane risk of bias tool for RCTs. Letters A-E denote the sources of bias listed in Table 1.
Fig 1 Conceptual framework that underlies the Cochrane risk of bias tool for RCTs. Letters A-E denote the sources of bias listed in Table 1.CC BY · PubMed Central
Fig 2 Flow diagram of identification, screening, and inclusion of trials.
Fig 2 Flow diagram of identification, screening, and inclusion of trials.CC BY · PubMed Central
Fig 3 Random-effects meta-analysis of RORs associated with inadequate/unclear (versus adequate) sequence generation. The boxed section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study (however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR is (95% CrI) 0.89 (0.82, 0.96)]. The BRANDO 2012b ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95% CrI) is 0.89 (0.75, 1.05)]. The Unverzagt 2013c ROR is based on a multivariable analysis with adjustment for allocation concealment, double blinding, attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.98 (0.8, 1.21)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95% CrI) is 0.99 (0.84, 1.16)]. The BRANDO 2012e ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95% CrI) is 0.83 (0.74, 0.94)].
Fig 3 Random-effects meta-analysis of RORs associated with inadequate/unclear (versus adequate) sequence generation. The boxed section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study (however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR is (95% CrI) 0.89 (0.82, 0.96)]. The BRANDO 2012b ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95% CrI) is 0.89 (0.75, 1.05)]. The Unverzagt 2013c ROR is based on a multivariable analysis with adjustment for allocation concealment, double blinding, attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.98 (0.8, 1.21)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95% CrI) is 0.99 (0.84, 1.16)]. The BRANDO 2012e ROR is based on a multivariable analysis with adjustment for allocation concealment and double blinding [the corresponding univariable ROR (95% CrI) is 0.83 (0.74, 0.94)].CC BY · PubMed Central
Fig 4 Random-effects meta-analysis of RORs associated with inadequate/unclear (versus adequate) allocation concealment. The boxed section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study (however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.93 (0.87, 0.99)]. The BRANDO 2012b ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.98 (0.88, 1.10)]. The BRANDO 2012c ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.97 (0.85, 1.10)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.85 (0.75, 0.95)].
Fig 4 Random-effects meta-analysis of RORs associated with inadequate/unclear (versus adequate) allocation concealment. The boxed section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study (however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.93 (0.87, 0.99)]. The BRANDO 2012b ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.98 (0.88, 1.10)]. The BRANDO 2012c ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.97 (0.85, 1.10)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for sequence generation and double blinding [the corresponding univariable ROR (95% CrI) is 0.85 (0.75, 0.95)].CC BY · PubMed Central
Fig 5 Random-effects meta-analysis of RORs and dSMDs associated with presence (versus absence) of baseline imbalance. The Unverzagt 2013a ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, double blinding, attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.92 (0.80, 1.06)].
Fig 5 Random-effects meta-analysis of RORs and dSMDs associated with presence (versus absence) of baseline imbalance. The Unverzagt 2013a ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, double blinding, attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.92 (0.80, 1.06)].CC BY · PubMed Central
Fig 6 Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of participants (versus blinding of participants).
Fig 6 Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of participants (versus blinding of participants).CC BY · PubMed Central
Fig 7 Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of personnel or participants/personnel (versus blinding of either party).
Fig 7 Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of personnel or participants/personnel (versus blinding of either party).CC BY · PubMed Central
Fig 8 Estimated RORs and dSMDs associated with any (versus no or minimal) attrition. The boxed section displays the average bias estimates, where available, from the four meta-epidemiological studies contributing to the BRANDO 2012 study. The Abraha 2015a ROR is based on a multivariable analysis with adjustment for use of placebo comparison, sample size, type of centre, items of risk of bias, post-randomisation exclusions, funding, and publication bias [the corresponding univariable ROR (95% CI) is 0.83 (0.71, 0.97)]. The Unverzagt 2013b ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, double blinding, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 1.19 (0.98, 1.45)]. The Nuesch 2009bc dSMD is based on a multivariable analysis with adjustment for allocation concealment [the corresponding multivariable dSMD (95% CI) with adjustment for blinding of participants is -0.15 (-0.30, 0.00), and the corresponding univariable dSMD (95% CI) is -0.13 (-0.29, 0.04)].
Fig 8 Estimated RORs and dSMDs associated with any (versus no or minimal) attrition. The boxed section displays the average bias estimates, where available, from the four meta-epidemiological studies contributing to the BRANDO 2012 study. The Abraha 2015a ROR is based on a multivariable analysis with adjustment for use of placebo comparison, sample size, type of centre, items of risk of bias, post-randomisation exclusions, funding, and publication bias [the corresponding univariable ROR (95% CI) is 0.83 (0.71, 0.97)]. The Unverzagt 2013b ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, double blinding, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 1.19 (0.98, 1.45)]. The Nuesch 2009bc dSMD is based on a multivariable analysis with adjustment for allocation concealment [the corresponding multivariable dSMD (95% CI) with adjustment for blinding of participants is -0.15 (-0.30, 0.00), and the corresponding univariable dSMD (95% CI) is -0.13 (-0.29, 0.04)].CC BY · PubMed Central
Fig 9 Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of outcome assessors (versus blinding of outcome assessors). RHR = Ratio of hazard ratios. Hróbjartsson 2014aa “standard trials” comprise those comparing experimental interventions with standard control interventions, such as placebo, no-treatment, usual care or active control. Hróbjartsson 2014ab “atypical trials” comprise those comparing an oral experimental administration of a drug with the intravenous control administration of the same drug for cytomegalovirus retinitis.
Fig 9 Random-effects meta-analysis of RORs and dSMDs associated with lack of/unclear blinding of outcome assessors (versus blinding of outcome assessors). RHR = Ratio of hazard ratios. Hróbjartsson 2014aa “standard trials” comprise those comparing experimental interventions with standard control interventions, such as placebo, no-treatment, usual care or active control. Hróbjartsson 2014ab “atypical trials” comprise those comparing an oral experimental administration of a drug with the intravenous control administration of the same drug for cytomegalovirus retinitis.CC BY · PubMed Central
Fig 10 Random-effects meta-analysis of RORs associated with lack of/unclear double blinding (versus double blinding). The boxed section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study (however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.87 (0.79, 0.96)]. The BRANDO 2012b ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.92 (0.80, 1.04)]. The Unverzagt 2013c ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.84 (0.69, 1.02)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.93 (0.74, 1.18)]. The BRANDO 2012e ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.78 (0.65, 0.92)].
Fig 10 Random-effects meta-analysis of RORs associated with lack of/unclear double blinding (versus double blinding). The boxed section displays the average bias estimates, where available, from the seven meta-epidemiological studies contributing to the BRANDO 2012a study (however only the BRANDO 2012a ROR was included in our meta-analysis). The BRANDO 2012a ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.87 (0.79, 0.96)]. The BRANDO 2012b ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.92 (0.80, 1.04)]. The Unverzagt 2013c ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, attrition, selective outcome reporting, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.84 (0.69, 1.02)]. The BRANDO 2012d ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.93 (0.74, 1.18)]. The BRANDO 2012e ROR is based on a multivariable analysis with adjustment for sequence generation and allocation concealment [the corresponding univariable ROR (95% CrI) is 0.78 (0.65, 0.92)].CC BY · PubMed Central
Fig 11 Random-effects meta-analysis of RORs and dSMDs associated with high/unclear (versus low) risk of bias due to selective reporting. The Unverzagt 2013a ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, double blinding, attrition, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.73 (0.54, 0.98)].
Fig 11 Random-effects meta-analysis of RORs and dSMDs associated with high/unclear (versus low) risk of bias due to selective reporting. The Unverzagt 2013a ROR is based on a multivariable analysis with adjustment for sequence generation, allocation concealment, double blinding, attrition, early stopping, pre-intervention, competing interests, baseline imbalance, switching interventions, sufficient follow-up, and single- versus multi-centre status [the corresponding univariable ROR (95% CI) is 0.73 (0.54, 0.98)].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Research works printed but not linked: 2

  1. The Oxford 2011 Levels of Evidence
  2. Als-Nielsen B, Chen W, Gluud LL, Siersma V, Hilden J, Gluud C. Are trial size and reported methodological quality associated with treatment effects? Observational study of 523 randomised trials [abstract]. 12th Cochrane Colloquium: Bridging the Gaps; 2004 Oct 2–6; Ottawa, Ontario, Canada [Internet]. 2004:[102–3 pp.]. Available: http://onlinelibrary.wiley.com/o/cochrane/clcmr/articles/CMR-6643/frame.html.

Cited by

See all 284

Metadata

Authors
Page, M. J., Higgins, J. P. T., Clayton, G., Sterne, J. A. C., Hróbjartsson, A., & Savović, J.
Affiliations
  • University of Bristol (GB)
  • University of Southern Denmark (DK)
  • University Hospitals Bristol NHS Foundation Trust (GB)
Corresponding author
Page, Matthew J.
Venue
PLOS ONE
Published
2016-07-11
Volume
11
Issue
7
Pages
e0159267
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2461177968
Cited by
284
References
64
Citations by year
2026: 24 · 2025: 22 · 2024: 25 · 2023: 29 · 2022: 45 · 2021: 35 · 2020: 33 · 2019: 32 · 2018: 21 · 2017: 14 · 2016: 3
FWCI
7.97
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, other-oa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Bristol Research (University of Bristol) (submittedVersion, cc-by)
  • Explore Bristol Research (submittedVersion, cc-by)
Funders
  • MRC Network of Hubs for Trials Methodology Research (MR/L004933/1- N61)
  • National Health and Medical Research Council (1088535)
  • National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West)
Topics
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Keywords
study design bias, meta-epidemiology, sequence generation, allocation concealment, blinding, double blinding, subjective outcomes, objective outcomes, attrition, selective attrition, reporting quality, trial heterogeneity, standardized mean difference
MeSH terms
Humans, Bias, Epidemiologic Studies, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies. https://app.cochat.ai/papers/10.1371/journal.pone.0159267
The paper
Page, M. J., Higgins, J. P. T., Clayton, G., Sterne, J. A. C., Hróbjartsson, A., & Savović, J. (2016). Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies. PLOS ONE. https://doi.org/10.1371/journal.pone.0159267

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.